AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7848890
Drug: IV vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vinorelbine (30 mg/m2 weekly)
Trial: 3184107
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily hydrocortisone replacement
Trial: 3184107
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily hydrocortisone replacement
Trial: 26387934
Drug: Oocyte retrieval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oocyte retrieval at 36 hours post-HCG administration (n = 78)
Trial: 26387934
Drug: Oocyte retrieval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oocyte retrieval at 38 hours post-HCG administration (n = 78)
Trial: 15257791
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg loading dose of beta-artemether
Trial: 15257791
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg loading dose of beta-artemether
Trial: 11567707
Drug: Chemoprevention treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoprevention treatment trials
Trial: 8465173
Drug: Toluene exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toluene exposure at 2 mg.min-1 for 3 hours
Trial: 8465173
Drug: Toluene exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toluene exposure at 6 mg.min-1 for 30 minutes
Trial: 8465173
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion at 0.08 g.kg-1 during toluene exposure at 2 mg.min-1
Trial: 8465173
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion at 0.16 g.kg-1 during toluene exposure at 2 mg.min-1
Trial: 8465173
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion at 0.32 g.kg-1 during toluene exposure at 2 mg.min-1
Trial: 7870932
Drug: Ethanol administration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol administration
Trial: 29885163
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D along with metformin
Trial: 19505384
Drug: Aerosol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol treatment with thiamphenicol glycinate acetylcysteinate (250 mg/day in 2 administrations) plus beclomethasone (400 microg/day in 2 administrations) for 10 days/month over a period of 6 months.
Trial: 19505384
Drug: Aerosol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol treatment with thiamphenicol glycinate acetylcysteinate plus beclomethasone.
Trial: 17126337
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone (300 mg daily for 6 weeks)
Trial: 17126337
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone (30 mg daily for 6 weeks)
Trial: 7619569
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment (dry powder inhalations of either salbutamol 1600 micrograms or ipratropium bromide 160 micrograms daily)
Trial: 7619569
Drug: On demand
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On demand treatment (only during exacerbations or periods of dyspnoea)
Trial: 25237669
Drug: 11-mm implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-mm implant combined with maxillary sinus floor elevation surgery
Trial: 25237669
Drug: 6-mm implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm implant without any grafting
Trial: 18191521
Drug: Late-switch group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-switch group received liposomal AmB only when sCr increase was >=100% or sCr reached 170mumol/L
Trial: 15812080
Drug: Concurrent cisplatin-radiotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin-radiotherapy (CRT)
Trial: 10635419
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg thrice daily for 10 days)
Trial: 7926531
Drug: Low-osmolality, nonionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-osmolality, nonionic contrast agent (Omnipaque 300; iohexol, 672 mOsm/kg H2O)
Trial: 7926531
Drug: High-osmolality, ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-osmolality, ionic contrast agent (Hypaque 50%; diatrizoate sodium, 1515 mOsm/kg H20)
Trial: 795256
Drug: Cimetidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (0.8 g daily)
Trial: 30790446
Drug: Rosuvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin treatment for 6 months
Trial: 28641582
Drug: IV levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV levetiracetam infusion (40 mg/kg over 5 min)
Trial: 28641582
Drug: IV phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV phenytoin infusion (20 mg/kg over 20 min)
Trial: 18503138
Drug: Octostim nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octostim nasal spray (300 mug)
Trial: 17027358
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (100 microg) administered to all individuals, followed by retesting of hormone levels after 4 hours.
Trial: 17027358
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration for patients with beta-thalassemia and low T levels.
Trial: 8838438
Drug: Loperamide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Trial: 8838438
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Trial: 2938194
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ipratropium combined with 1.25 mg, 2.5 mg or 5.0 mg fenoterol
Trial: 2938194
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg salbutamol
Trial: 2938194
Drug: Combined preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparations (ipratropium and fenoterol)
Trial: 27689549
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment conditions
Trial: 23686640
Drug: GSD (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSD (oral glucose spray) - 10 puffs delivering 50 mg of glucose per puff
Trial: 17944738
Drug: Low-volume 5-aminosalicylic
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume 5-aminosalicylic acid foam (2 x 1 g/30 mL)
Trial: 17944738
Drug: High-volume 5-aminosalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume 5-aminosalicylic acid foam (2 x 1 g/60 mL)
Trial: 9884941
Drug: Modified preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified preparation (13.9‐17.6 GBq 99mTcO4‐)
Trial: 9884941
Drug: Regular preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular preparation (4.4‐8.8 GBq 99mTcO4‐)
Trial: 7532938
Drug: Tranilast and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast and local treatment (nasal and tubal)
Trial: 7532938
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment (control for Group A)
Trial: 3061819
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of perindopril once daily
Trial: 3061819
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of perindopril once daily
Trial: 3061819
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of perindopril once daily
Trial: 26073355
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Rosuvastatin tablet formulation 1
Trial: 26073355
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Rosuvastatin tablet formulation 2
Trial: 18082788
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment with fibrinolytics
Trial: 18082788
Drug: Adjunctive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapies including beta-blockers, aspirin (or clopidogrel if aspirin is contraindicated), nitroglycerin, and analgesia
Trial: 18082788
Drug: Clopidogrel as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel as adjunctive therapy for patients undergoing fibrinolysis
Trial: 18082788
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin and low-molecular-weight heparin as adjunctives
Trial: 18082788
Drug: Multiple new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple new antithrombin agents
Trial: 12817175
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg (DBPC trials)
Trial: 12817175
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg (PROBE trials)
Trial: 9105068
Drug: Salmeterol 100
RxNorm normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 100 microg twice a day
Trial: 3888863
Drug: Naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1000 mg daily
Trial: 8252318
Drug: Naproxen 1500
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 1500 mg daily
Trial: 8252318
Drug: Naproxen combined
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen combined with 4 g paracetamol daily
Trial: 8252318
Drug: Lower naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower naproxen doses with paracetamol
Trial: 3515924
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine 650 mg + 60 mg
Trial: 29116880
Drug: C. difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. difficile vaccine
Trial: 21911650
Drug: Subretinal gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal gene therapy using recombinant adeno‐associated virus 2 (rAAV2) carrying the RPE65 gene
Trial: 21911650
Drug: Subretinal gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal gene therapy
Trial: 20089951
Drug: Acyclovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (400 mg orally twice daily)
Trial: 17884802
Drug: Mandibular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular nerve block (MNB) with ropivacaine 10 mg ml(‐1)
Trial: 11163559
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal saline injection)
Trial: 9661575
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg/kg preoperatively and 8 mg.kg‐1.h‐1 intraoperatively
Trial: 8697927
Drug: Lansoprazole (L)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (L)
Trial: 29956034
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy (Habit reversal training and exposure response prevention)
Trial: 29956034
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (Habit reversal training and exposure response prevention)
Trial: 29956034
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (Individual and Group)
Trial: 27716668
Drug: Potentially Inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially Inappropriate Medications (PIM) identified using the Priscus list
Trial: 27716668
Drug: PIM prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIM prescription rates
Trial: 19639690
Drug: Intranasal electrophoresis
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal electrophoresis using mexidol
Trial: 17910224
Drug: 16% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16% carbamide peroxide gel
Trial: 17910224
Drug: 30% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% carbamide peroxide gel
Trial: 15851743
Drug: Nighttime pergolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nighttime pergolide (1 mg)
Trial: 11805862
Drug: Serotonin agonist
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin agonist (buspirone hydrochloride)
Trial: 8750367
Drug: High-dose aerosolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month or 600 mg once a month)
Trial: 8750367
Drug: Standard-dose aerosolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose aerosolized pentamidine prophylaxis (300 mg once a month)
Trial: 8750367
Drug: High-dose aerosolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosolized pentamidine prophylaxis (300 mg twice a month)
Trial: 8750367
Drug: High-dose aerosolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosolized pentamidine prophylaxis (600 mg once a month)
Trial: 8750367
Drug: High-dose aerosolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosolized pentamidine prophylaxis
Trial: 6995186
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg griseofulvin-FP daily for 8 weeks
Trial: 31950977
Drug: Histamine-2 Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 Receptor Blockers (H2RBs)
Trial: 31003878
Drug: Chemotherapy-induced peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced peripheral neuropathy (CIPN) assessment and management communication
Trial: 26990171
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 μg BID
Trial: 22934930
Drug: NAL prescription
RxNorm normalized name: Foster & Thrive All Day Allergy Original Prescription Strength 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL prescription for hearing aids
Trial: 22934930
Drug: DSL prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSL prescription for hearing aids
Trial: 19969160
Drug: Ultrasonography-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography-guided injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Trial: 19969160
Drug: Blind injection
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind injection of 20 mg triamcinolone mixed with 1.5 mL 2% lidocaine and 4 mL normal saline followed by 5 weekly injections of sodium hyaluronate
Trial: 14998846
Drug: PLD 50
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 50 mg/m2 (every 4 weeks)
Trial: 14998846
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 (every 3 weeks)
Trial: 9532992
Drug: Transcervical amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical amnioinfusion of 500 mL saline over 30 minutes, then 500 mL at 30 drops per minute
Trial: 2684660
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg kg‐1 i.v. followed by a ketamine infusion of 2 mg kg‐1 h‐1
Trial: 28070862
Drug: CAM2038 q4w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 q4w 96 mg
Trial: 28070862
Drug: CAM2038 q4w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 q4w 192 mg
Trial: 28070862
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine 8, 16, or 24 mg daily for 7 days
Trial: 28070862
Drug: CAM2038 q1w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 q1w 16 mg
Trial: 19465880
Drug: Fluoxetine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine alone (n = 109)
Trial: 19465880
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy alone (n = 111)
Trial: 19465880
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (n = 107)
Trial: 16959450
Drug: Lidocaine-prilocaine (EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine (EMLA patch 5%)
Trial: 8141714
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) and subcutaneous heparin
Trial: 8141714
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (SK) and intravenous heparin
Trial: 8141714
Drug: Tissue plasminogen
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tissue plasminogen activator (t‐PA) and intravenous heparin
Trial: 8141714
Drug: Combination t‐PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination t‐PA and SK
Trial: 2469654
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution
Trial: 29590007
Drug: Low-dose Abiraterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Abiraterone (250 mg with a low-fat meal)
Trial: 29590007
Drug: Standard-dose Abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Abiraterone (1,000 mg fasting)
Trial: 29590007
Drug: Low-dose Abiraterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Abiraterone
Trial: 29590007
Drug: Standard-dose Abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Abiraterone
Trial: 27421538
Drug: Oral 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17β‐estradiol 1 mg/d
Trial: 25161816
Drug: Short-term psychotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychotherapy (psychodynamic or solution-focused)
Trial: 18755584
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) based first-line chemotherapy
Trial: 12532114
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (mattress and pillow encasings)
Trial: 12490967
Drug: Ciprofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate (100 mg once daily for 16 weeks)
Trial: 9873260
Drug: HIV-infected patients
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected patients with haemophilia A with inhibitors
Trial: 9873260
Drug: HIV-infected patients
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected patients with haemophilia A without inhibitors
Trial: 8138763
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of raised serum cholesterol concentration (> or = 6.5 mmol/l) after education intervention